Further, the present study indicates that three genes (NLRP1, NOD2 and TLR6) measured at baseline appear to be highly predictive of TB treatment completion, suggesting a potential as a minimal signature for monitoring and tailoring (“personalizing”) anti-TB therapy. The gene discussed is NOD2; the disease is tuberculosis.